Clinical Trials Logo
  1. Home
  2. Tuberculous Meningitis
  3. NCT02237365

A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis — AspirinTBM  

Tuberculous Meningitis Clinical Trial

Official title:
A Pilot Phase II Randomized Controlled Double Blind Trial of 81mg Aspirin Daily vs. 1000 mg Aspirin Daily vs. Placebo as Adjunctive Therapy in HIV Negative Adults With Tuberculous Meningitis

Clinical Trial Summary

Tuberculous meningitis is a severe brain infection which often causes disability and death even when treated with the best available treatment. Aspirin is a type of anti-inflammation drug which can reduce the inflammatory response in brains of patients with tuberculous meningitis, and therefore may decrease some of the most severe outcomes. This study compares the use of aspirin (at 2 different doses) versus placebo as an additional therapy to the standard treatment to see if aspirin is safe and helpful in reducing disability and death from tuberculous meningitis. Patients will be treated with aspirin or placebo for 60 days and followed up while on standard treatment for 8 months.

Clinical Trial Description

The study is a parallel group, double blind, randomised, placebo controlled trial of 60 days treatment with placebo vs. 81mg daily dose vs. 1000mg daily dose aspirin for the treatment of HIV-uninfected adults with tuberculous meningitis.

All patients will receive standard anti-tuberculous chemotherapy and adjunctive dexamethasone, according to Viet Nam National Tuberculosis Programme guidelines. Participants will be stratified by Medical Research Council UK disease severity grade, and randomized at enrollment to one of three study arms (1:1:1 ratio). Patients will be admitted to hospital for at least the first 14 days of study treatment enabling real-time active surveillance of any adverse events after which they will be discharged according to clinical care with continued monitoring.

A schedule of clinical and laboratory monitoring including lumbar puncture, pharmacokinetic assessment of peripheral blood monocyte/macrophage antimicrobial activity, clinical assessments, brain magnetic resonance imaging (MRI) and neurological assessment will manage patient safety and capture study outcomes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02237365
Study type Interventional
Source Oxford University Clinical Research Unit, Vietnam
Contact
Status Completed
Phase Phase 2
Start date October 17, 2014
Completion date December 22, 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT01371916 - Diagnosis of Tuberculous Meningitis by ESAT-6 in CSF N/A
Active, not recruiting NCT00433719 - Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis N/A
Not yet recruiting NCT02588196 - The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Phase 4
Completed NCT03092817 - Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) Phase 3
Recruiting NCT03787940 - Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis N/A
Not yet recruiting NCT05917340 - Intensified Short Course Regimen for TBM in Adults Phase 3
Completed NCT01802502 - Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation Phase 2
Recruiting NCT05636254 - Diagnostic Accuracy of Imaging Findings in TBM/Spinal Tubercular Arachnoiditis and Correlation With Outcomes
Recruiting NCT03898635 - Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
Completed NCT05781646 - Xpert MTB/RIF Assay for Diagnosis of Tuberculous Meningitis (TBM) in Maharaj Nakorn Chiang Mai Hospital N/A
Active, not recruiting NCT03100786 - Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis Phase 3
Recruiting NCT04145258 - Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis Phase 3
Recruiting NCT05383742 - Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis Phase 2
Completed NCT03226379 - Driving Reduced AIDS-associated Meningo-encephalitis Mortality N/A
Recruiting NCT05590455 - Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis Phase 2
Recruiting NCT04308928 - Evaluation of New Biomarker-based Approaches for Improving the Diagnosis of Childhood Tuberculous Meningitis